As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 470 Wildwood Ave, Woburn, MA 01801 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
On March 18, Medicilon hosted a CFDA IND seminar with Korea Pharmaceutical Manufacturers Association (KPMA) in Seoul, South Korea. The seminar’s topic was “Experience Sharing and Exchange on CFDA’s IND Application and Drug Development Collaboration”
There were more than 50 companies with about 130 pharmaceutical experts and scientists to attend this seminar. Dr. Chunlin Chen, Medicilon’s CEO, shared his experience on CFDA IND filing, to the Korean clients. Dr. Chen explained clearly about the process of IND filing in China during the presentation. After the presentation, the experts and scientists showed strong interested in the Medicilon’s IND services and had a further discussion on the possibilities of collaboration with Medicilon.
Medicilon’s IND Filing-innovative drug research and development
Medicilon successfully held CFDA IND seminar in Seoul, South Korea
Medicilon sponsored the seminar on new drug preclinical research and IND application strategy